Triple Negative Breast Cancer : Reviewing Abstracts Published by Authors Junjie Li & XI Wang
Triple Negative Breast Cancer
Speaker :
Dr. Babita Kataria, Medical Oncologist, Delhi
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Author: Junjie Li
Citation: Journal of Clinical Oncology 38, no. 16 (June 01, 2020) 1774-1784
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Author: XI Wang
Citation: JAMA. Published online December 10, 2020. doi:10.1001/jama.2020.23370
Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001)
Author: XI Wang
Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 507-507